-
Je něco špatně v tomto záznamu ?
Long-term dopaminergic therapy improves spoken language in de-novo Parkinson's disease
M. Subert, T. Tykalova, M. Novotny, O. Bezdicek, P. Dusek, J. Rusz
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, pozorovací studie
Grantová podpora
NW24-04-00211
Ministerstvo Zdravotnictví Ceské Republiky
NU21-04-00535
Ministerstvo Zdravotnictví Ceské Republiky
MH CZ-DRO-VFN64165
Ministerstvo Zdravotnictví Ceské Republiky
LX22NPO5107
Ministerstvo Školství, Mládeže a Tělovýchovy
SGS23/170/OHK3/3T/13
České Vysoké Učení Technické v Praze
- MeSH
- agonisté dopaminu * terapeutické užití MeSH
- antiparkinsonika * terapeutické užití MeSH
- dopaminové látky * terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- Parkinsonova nemoc * farmakoterapie komplikace MeSH
- řeč * účinky léků MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
BACKGROUND AND OBJECTIVES: The impact of dopaminergic medication on language in Parkinson's disease (PD) remains poorly understood. This observational, naturalistic study aimed to investigate the effects of long-term dopaminergic therapy on language performance in patients with de-novo PD based on a high-level linguistic analysis of natural spontaneous discourse. METHODS: A fairy-tale narration was recorded at baseline and a 12-month follow-up. The speech samples were automatically analyzed using six representative lexical and syntactic features based on automatic speech recognition and natural language processing. RESULTS: We enrolled 109 de-novo PD patients compared to 68 healthy controls. All subjects completed the 12-month follow-up; 92 PD patients were on stable dopaminergic medication (PD-treated), while 17 PD patients remained without medication (PD-untreated). At baseline, the PD-treated group exhibited abnormalities in syntactic domains, particularly in sentence length (p = 0.018) and sentence development (p = 0.042) compared to healthy controls. After 12 months of dopaminergic therapy, PD-treated showed improvements in the syntactic domain, including sentence length (p = 0.012) and sentence development (p = 0.030). Of all PD-treated patients, 37 were on monotherapy with dopamine agonists and manifested improvement in sentence length (p = 0.048), while 32 were on monotherapy with levodopa and had no language amelioration. No changes in language parameters over time were seen in both the PD-untreated group and healthy controls. DISCUSSION: Initiation of dopaminergic therapy improved high-language syntactic deficits in de-novo PD, confirming the role of dopamine in cognitive-linguistic processing. Automated linguistic analysis of spontaneous speech via natural language processing can assist in improving the prediction and management of language deficits in PD.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016084
- 003
- CZ-PrNML
- 005
- 20250731091514.0
- 007
- ta
- 008
- 250708s2025 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00415-025-13070-8 $2 doi
- 035 __
- $a (PubMed)40244335
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Subert, Martin $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Technická 2, Praha 6, 160 00, Prague, Czech Republic
- 245 10
- $a Long-term dopaminergic therapy improves spoken language in de-novo Parkinson's disease / $c M. Subert, T. Tykalova, M. Novotny, O. Bezdicek, P. Dusek, J. Rusz
- 520 9_
- $a BACKGROUND AND OBJECTIVES: The impact of dopaminergic medication on language in Parkinson's disease (PD) remains poorly understood. This observational, naturalistic study aimed to investigate the effects of long-term dopaminergic therapy on language performance in patients with de-novo PD based on a high-level linguistic analysis of natural spontaneous discourse. METHODS: A fairy-tale narration was recorded at baseline and a 12-month follow-up. The speech samples were automatically analyzed using six representative lexical and syntactic features based on automatic speech recognition and natural language processing. RESULTS: We enrolled 109 de-novo PD patients compared to 68 healthy controls. All subjects completed the 12-month follow-up; 92 PD patients were on stable dopaminergic medication (PD-treated), while 17 PD patients remained without medication (PD-untreated). At baseline, the PD-treated group exhibited abnormalities in syntactic domains, particularly in sentence length (p = 0.018) and sentence development (p = 0.042) compared to healthy controls. After 12 months of dopaminergic therapy, PD-treated showed improvements in the syntactic domain, including sentence length (p = 0.012) and sentence development (p = 0.030). Of all PD-treated patients, 37 were on monotherapy with dopamine agonists and manifested improvement in sentence length (p = 0.048), while 32 were on monotherapy with levodopa and had no language amelioration. No changes in language parameters over time were seen in both the PD-untreated group and healthy controls. DISCUSSION: Initiation of dopaminergic therapy improved high-language syntactic deficits in de-novo PD, confirming the role of dopamine in cognitive-linguistic processing. Automated linguistic analysis of spontaneous speech via natural language processing can assist in improving the prediction and management of language deficits in PD.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Parkinsonova nemoc $x farmakoterapie $x komplikace $7 D010300
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a antiparkinsonika $x terapeutické užití $7 D000978
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a dopaminové látky $x terapeutické užití $7 D015259
- 650 12
- $a agonisté dopaminu $x terapeutické užití $7 D018491
- 650 12
- $a řeč $x účinky léků $7 D013060
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Tykalova, Tereza $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Technická 2, Praha 6, 160 00, Prague, Czech Republic
- 700 1_
- $a Novotny, Michal $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Technická 2, Praha 6, 160 00, Prague, Czech Republic
- 700 1_
- $a Bezdicek, Ondrej $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Dusek, Petr $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Rusz, Jan $u Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University in Prague, Technická 2, Praha 6, 160 00, Prague, Czech Republic. rusz.mz@gmail.com $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. rusz.mz@gmail.com $u ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland. rusz.mz@gmail.com $1 https://orcid.org/0000000210363054 $7 xx0093732
- 773 0_
- $w MED00002835 $t Journal of neurology $x 1432-1459 $g Roč. 272, č. 5 (2025), s. 344
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40244335 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091509 $b ABA008
- 999 __
- $a ok $b bmc $g 2366734 $s 1253209
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 272 $c 5 $d 344 $e 20250417 $i 1432-1459 $m Journal of neurology $n J Neurol $x MED00002835
- GRA __
- $a NW24-04-00211 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NU21-04-00535 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a MH CZ-DRO-VFN64165 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a LX22NPO5107 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a SGS23/170/OHK3/3T/13 $p České Vysoké Učení Technické v Praze
- LZP __
- $a Pubmed-20250708